Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis

J Intern Med. 2021 Jan;289(1):125-128. doi: 10.1111/joim.13183. Epub 2020 Oct 20.

Authors

C S Kow¹, S S Hasan^{2

3}

Affiliations

¹ School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
² Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom.
³ School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, NSW, Australia.

PMID: 33078881
DOI: 10.1111/joim.13183

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Coinfection*
Humans
Proton Pump Inhibitors / adverse effects
Respiratory Distress Syndrome*
Risk Factors
SARS-CoV-2

Substances

Proton Pump Inhibitors